Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE37.2500
- TODAY'S CHANGE (%)-0.7900 (-2.0768%)
- Bid / Lots35.0000/ 1
- Ask / Lots37.2500/ 1
- Open / Previous Close37.7500 / 38.0400
- Day Range
- 52 Week Range
- Volume273,938
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 843 | 37.76 |
| 09:43 ET | 100 | 37.5 |
| 09:52 ET | 200 | 37.37 |
| 09:56 ET | 200 | 37.04 |
| 09:57 ET | 400 | 37.02 |
| 09:59 ET | 100 | 37.02 |
| 10:01 ET | 2769 | 37.16 |
| 10:03 ET | 100 | 37.195 |
| 10:10 ET | 100 | 37.2 |
| 10:12 ET | 100 | 37.04 |
| 10:14 ET | 100 | 37.305 |
| 10:17 ET | 1981 | 37.04 |
| 10:19 ET | 500 | 37.13 |
| 10:21 ET | 400 | 37.29 |
| 10:24 ET | 1800 | 37.22 |
| 10:26 ET | 600 | 36.94 |
| 10:28 ET | 200 | 37.095 |
| 10:30 ET | 1438 | 37.07 |
| 10:32 ET | 1000 | 37.08 |
| 10:33 ET | 400 | 36.93 |
| 10:35 ET | 218 | 37.135 |
| 10:39 ET | 1220 | 36.84 |
| 10:42 ET | 200 | 36.82 |
| 10:44 ET | 800 | 36.81 |
| 10:46 ET | 1888 | 36.88 |
| 10:50 ET | 1899 | 37.1075 |
| 10:51 ET | 100 | 37.18 |
| 10:53 ET | 1100 | 37.19 |
| 10:55 ET | 600 | 37.125 |
| 10:57 ET | 100 | 37.25 |
| 11:00 ET | 200 | 37.342 |
| 11:02 ET | 100 | 37.34 |
| 11:04 ET | 100 | 37.34 |
| 11:08 ET | 600 | 37.175 |
| 11:09 ET | 636 | 37.1 |
| 11:11 ET | 200 | 37.095 |
| 11:15 ET | 300 | 37.1 |
| 11:18 ET | 400 | 37.01 |
| 11:20 ET | 200 | 36.98 |
| 11:22 ET | 400 | 36.93 |
| 11:24 ET | 336 | 36.87 |
| 11:26 ET | 1500 | 36.91 |
| 11:27 ET | 200 | 36.91 |
| 11:29 ET | 200 | 36.89 |
| 11:31 ET | 1071 | 36.9 |
| 11:33 ET | 5712 | 37.36 |
| 11:36 ET | 718 | 37.17 |
| 11:38 ET | 300 | 37.185 |
| 11:44 ET | 100 | 37.12 |
| 11:45 ET | 100 | 37.165 |
| 11:49 ET | 200 | 37.15 |
| 11:51 ET | 10400 | 36.96 |
| 11:54 ET | 200 | 36.95 |
| 11:58 ET | 100 | 37.02 |
| 12:00 ET | 436 | 36.95 |
| 12:02 ET | 200 | 36.95 |
| 12:03 ET | 300 | 36.86 |
| 12:07 ET | 400 | 36.9 |
| 12:09 ET | 100 | 36.89 |
| 12:12 ET | 804 | 36.975 |
| 12:14 ET | 526 | 37.01 |
| 12:16 ET | 1200 | 37.07 |
| 12:18 ET | 300 | 37.04 |
| 12:21 ET | 100 | 37.01 |
| 12:23 ET | 200 | 36.94 |
| 12:27 ET | 300 | 36.95 |
| 12:30 ET | 2090 | 36.965 |
| 12:32 ET | 911 | 36.97 |
| 12:34 ET | 100 | 36.955 |
| 12:36 ET | 2536 | 36.915 |
| 12:38 ET | 200 | 36.875 |
| 12:39 ET | 400 | 36.945 |
| 12:41 ET | 200 | 36.94 |
| 12:43 ET | 300 | 36.96 |
| 12:45 ET | 100 | 36.965 |
| 12:48 ET | 450 | 36.965 |
| 12:50 ET | 100 | 36.97 |
| 12:52 ET | 500 | 37.02 |
| 12:54 ET | 900 | 36.99 |
| 12:56 ET | 700 | 36.94 |
| 12:57 ET | 300 | 36.94 |
| 12:59 ET | 100 | 36.9475 |
| 01:03 ET | 100 | 36.93 |
| 01:06 ET | 100 | 36.95 |
| 01:10 ET | 234 | 36.93 |
| 01:14 ET | 100 | 36.95 |
| 01:15 ET | 100 | 36.96 |
| 01:19 ET | 2090 | 37.09 |
| 01:24 ET | 700 | 37.05 |
| 01:28 ET | 400 | 36.98 |
| 01:32 ET | 300 | 36.91 |
| 01:33 ET | 100 | 36.91 |
| 01:35 ET | 200 | 36.96 |
| 01:37 ET | 300 | 36.95 |
| 01:39 ET | 237 | 37.007 |
| 01:42 ET | 100 | 36.9 |
| 01:44 ET | 100 | 36.93 |
| 01:46 ET | 2276 | 36.965 |
| 01:51 ET | 131 | 36.99 |
| 01:53 ET | 350 | 36.985 |
| 01:55 ET | 19449 | 36.93 |
| 01:57 ET | 449 | 36.91 |
| 02:00 ET | 100 | 36.91 |
| 02:02 ET | 100 | 36.91 |
| 02:04 ET | 600 | 36.83 |
| 02:08 ET | 200 | 36.87 |
| 02:09 ET | 300 | 36.81 |
| 02:11 ET | 546 | 36.74 |
| 02:13 ET | 100 | 36.74 |
| 02:18 ET | 2698 | 36.58 |
| 02:20 ET | 100 | 36.58 |
| 02:22 ET | 662 | 36.575 |
| 02:26 ET | 200 | 36.6 |
| 02:27 ET | 1398 | 36.63 |
| 02:29 ET | 2080 | 36.645 |
| 02:31 ET | 616 | 36.69 |
| 02:33 ET | 200 | 36.74 |
| 02:36 ET | 1000 | 36.75 |
| 02:38 ET | 1137 | 36.7 |
| 02:40 ET | 300 | 36.72 |
| 02:42 ET | 1888 | 36.74 |
| 02:44 ET | 100 | 36.74 |
| 02:45 ET | 1219 | 36.88 |
| 02:47 ET | 300 | 36.87 |
| 02:49 ET | 100 | 36.88 |
| 02:51 ET | 100 | 36.88 |
| 02:54 ET | 200 | 36.87 |
| 02:58 ET | 3836 | 36.89 |
| 03:00 ET | 1164 | 36.975 |
| 03:02 ET | 1196 | 37.03 |
| 03:03 ET | 1300 | 37.145 |
| 03:05 ET | 1172 | 37.07 |
| 03:07 ET | 100 | 37.05 |
| 03:09 ET | 588 | 37.14 |
| 03:12 ET | 120 | 37.125 |
| 03:14 ET | 300 | 37.13 |
| 03:18 ET | 1637 | 37.21 |
| 03:20 ET | 100 | 37.23 |
| 03:21 ET | 507 | 37.23 |
| 03:23 ET | 962 | 37.25 |
| 03:25 ET | 900 | 37.28 |
| 03:30 ET | 900 | 37.36 |
| 03:32 ET | 301 | 37.43 |
| 03:34 ET | 3392 | 37.28 |
| 03:36 ET | 200 | 37.3 |
| 03:38 ET | 720 | 37.3 |
| 03:39 ET | 1439 | 37.25 |
| 03:41 ET | 2019 | 37.26 |
| 03:43 ET | 414 | 37.29 |
| 03:45 ET | 2748 | 37.39 |
| 03:48 ET | 310 | 37.38 |
| 03:50 ET | 2407 | 37.35 |
| 03:52 ET | 2498 | 37.34 |
| 03:54 ET | 4032 | 37.34 |
| 03:56 ET | 4624 | 37.205 |
| 03:57 ET | 5822 | 37.235 |
| 03:59 ET | 8303 | 37.25 |
Jun 5, 2024
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
May 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -13.7x | --- |
SpringWorks Therapeutics Inc | 2.9B | -7.5x | --- |
Structure Therapeutics Inc | 3.0B | -20.8x | --- |
Biohaven Ltd | 3.0B | -5.0x | --- |
Geron Corp | 3.0B | -14.1x | --- |
MoonLake Immunotherapeutics | 2.8B | -55.2x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -13.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
